Heike Keilhack

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle et al. · Proceedings of the National Academy of Sciences · 2013 · 757 citations · Full text

Engineering, Chemoprevention Strategy, Smarcb1-deleted Mrt Cells +24

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic et al. · Nature Chemical Biology · 2012 · 753 citations

Lymphoid Neoplasia, Medicine, Selective Inhibitor +8

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 597 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima et al. · Molecular Cancer Therapeutics · 2014 · 517 citations

Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Mohamed Bentires‐Alj, J. Guillermo Paez, Frank David et al. · Cancer Research · 2004 · 504 citations · Full text